---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224101"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-05-14T20:19:13+00:00"
generated_at: "2026-05-14T20:45:56.616394+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license

## Summary
- Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.
- Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director.
- Completed $30M private placement (pre-funded and common warrants); received $7.5M milestone from Boehringer.
- Exclusive license for CUE-221 (Phase 2 anti-IgE) from Ascendant Health; IND amendment for food allergy expected H2 2026.
- Cash $16.4M at Mar 31, 2026; subsequent $30M private placement extends runway for clinical milestones.

## SEC filing metadata
- accession: 0001193125-26-224101
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-05-14T20:19:13+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/0001193125-26-224101-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/cue-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224101
- JSON: https://secwatch.observer/filing/0001193125-26-224101.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224101.txt

## Key facts
- Earnings Releases
  Cue Biopharma, Inc. reported the quarter ended March 31, 2026 results: revenue $5.7 million, net income Net loss ... $5.2 million, EPS $(1.08) per common share – basic and diluted.
  - Period: the quarter ended March 31, 2026
  - Revenue: $5.7 million
  - Net income: Net loss ... $5.2 million
  - EPS: $(1.08) per common share – basic and diluted
  - Result: reported results
  source text: to the FDA in the second half of 2026 • Phase 1 first-in-human study expected to be initiated by year-end 2026. First Quarter 2026 Financial Results First quarter revenue was $5.7 million compared to $0.4 million in the first quarter of 2025. The revenue earned during the three months ended March 31, 2026 was related to the Boehringer Ingelheim collaboration and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526224101/0001193125-26-224101-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.